Stoke Therapeutics' (STOK) Buy Rating Reiterated at HC Wainwright

Stoke Therapeutics (NASDAQ:STOK - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $35.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 164.15% from the company's previous close.

Several other brokerages have also issued reports on STOK. Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Thursday, August 8th. Leerink Partnrs raised Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. Wedbush restated an "outperform" rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, Leerink Partners started coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They set an "outperform" rating and a $18.00 target price for the company. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $20.83.

Stoke Therapeutics Price Performance

NASDAQ STOK traded up $0.20 during trading hours on Wednesday, hitting $13.25. The company's stock had a trading volume of 496,645 shares, compared to its average volume of 763,043. The company has a market cap of $697.59 million, a P/E ratio of -6.08 and a beta of 0.95. The company's 50 day simple moving average is $13.24 and its two-hundred day simple moving average is $13.70. Stoke Therapeutics has a 12 month low of $3.77 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.11. The business had revenue of $4.83 million for the quarter, compared to the consensus estimate of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. As a group, research analysts predict that Stoke Therapeutics will post -2.1 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the company's stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now directly owns 8,906,181 shares of the company's stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 11.30% of the company's stock.

Institutional Trading of Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Lynx1 Capital Management LP raised its stake in shares of Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock valued at $70,052,000 after purchasing an additional 1,488,371 shares in the last quarter. Redmile Group LLC increased its stake in shares of Stoke Therapeutics by 93.2% during the first quarter. Redmile Group LLC now owns 5,073,049 shares of the company's stock valued at $68,486,000 after acquiring an additional 2,447,543 shares during the period. Baker BROS. Advisors LP raised its holdings in Stoke Therapeutics by 65.9% during the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company's stock worth $45,474,000 after purchasing an additional 1,338,309 shares in the last quarter. Vanguard Group Inc. lifted its position in Stoke Therapeutics by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company's stock worth $23,160,000 after purchasing an additional 67,052 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in shares of Stoke Therapeutics during the 2nd quarter valued at $19,835,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.